Diagnosis of drug-induced skin reactions: A future role for computer-aided systems?

Current Opinion in Allergy and Clinical Immunology

Volumn 11, Issue 5, 2011, Pages 451-456

  Burbach, Guido J ^a   Zuberbier, Torsten ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

cutaneous hypersensitivity reactions; decisional algorithms; European database; standardization

Indexed keywords

ABACAVIR; ALLOPURINOL; BLEOMYCIN; CARBAMAZEPINE; EPIDERMAL GROWTH FACTOR RECEPTOR; IMMUNOGLOBULIN E;

ACNE; ARTIFICIAL INTELLIGENCE; COMPUTER ASSISTED DIAGNOSIS; DERMATITIS; DIFFERENTIAL DIAGNOSIS; DRESS SYNDROME; DRUG HYPERSENSITIVITY; EPILUMINESCENCE MICROSCOPY; FIXED DRUG ERUPTION; HUMAN; INTRACUTANEOUS TEST; LYMPHOCYTE TRANSFORMATION TEST; MACULOPAPULAR RASH; MELANOCYTIC NEVUS; MELANOMA; PATCH TEST; PRICK TEST; PRIORITY JOURNAL; PROVOCATION TEST; REVIEW; SKIN ALLERGY; SKIN COLOR; SKIN EXAMINATION; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; URTICARIA; WHOLE BODY IMAGING;

ALGORITHMS; DECISION MAKING, COMPUTER-ASSISTED; DERMATOLOGY; DIAGNOSIS, COMPUTER-ASSISTED; DIAGNOSTIC IMAGING; DRUG HYPERSENSITIVITY; HUMANS; PRACTICE GUIDELINES AS TOPIC; SKIN; STATISTICS AS TOPIC;

EID: 80052493609     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0b013e32834a974c     Document Type: Review

References (55)

1. Roujeau JC. Clinical heterogeneity of drug hypersensitivity. Toxicology 2005; 209:123-129
2. Mirakian R, Ewan PW, Durham SR, et al. BSACI guidelines for the management of drug allergy. Clin Exp Allergy 2009; 39:43-61
3. Svensson CK, Cowen EW, Gaspari AA. Cutaneous drug reactions. Pharmacol Rev 2001; 53:357-379 (Pubitemid 32852017)
4. Drake LA, Dinehart SM, Farmer ER, et al. Guidelines of care for cutaneous adverse drug reactions. American Academy of Dermatology. J Am Acad Dermatol 1996; 35:458-461 (Pubitemid 26299238)
5. Bigby M, Jick S, Jick H, Arndt K. Drug-induced cutaneous reactions. A report from the Boston Collaborative Drug Surveillance Program on 15 438 consecutive inpatients, 1975 to 1982. J Am Med Assoc 1986; 256:3358-3363 (Pubitemid 17201796)
6. Badia M, Trujillano J, Gasco E, et al. Skin lesions in the ICU. Intensive Care Med 1999; 25:1271-1276
7. Rigel DS, Russak J, Friedman R. The evolution of melanoma diagnosis: 25 years beyond the ABCDs. CA Cancer J Clin 2010; 60:301-316
8. Friedman RJ, Rigel DS, Kopf AW. Early detection of malignant melanoma: the role of physician examination and self-examination of the skin. CA Cancer J Clin 1985; 35:130-151 (Pubitemid 15041543)
9. Rigel DS, Friedman RJ. The rationale of the ABCDs of early melanoma. J Am Acad Dermatol 1993; 29:1060-1061
10. Grob JJ, Bonerandi JJ. The 'ugly duckling' sign: identification of the common characteristics of nevi in an individual as a basis for melanoma screening. Arch Dermatol 1998; 134:103-104 (Pubitemid 28087124)
11. Stolz W, Riemann A, Cognetta AB, Pillet L. ABCD rule of dermatoscopy: a new practical method for early recognition of malignant melanoma. Eur J Dermatol 1994; 4:521-527 (Pubitemid 24349113)
12. Menzies SW, Ingvar C, Crotty KA, McCarthy WH. Frequency and morphologic characteristics of invasive melanomas lacking specific surface microscopic features. Arch Dermatol 1996; 132:1178-1182 (Pubitemid 26343965)
13. Argenziano G, Fabbrocini G, Carli P, et al. Epiluminescence microscopy for the diagnosis of doubtful melanocytic skin lesions; comparison of the ABCD rule of dermatoscopy and a new 7-point checklist based on pattern analysis. Arch Dermatol 1998; 134:1563-1570 (Pubitemid 29009257)
14. Henning JS, Dusza SW, Wang SQ, et al. The CASH (color, architecture, symmetry, and homogeneity) algorithm for dermoscopy. J Am Acad Dermatol 2007; 56:45-52 (Pubitemid 44969304)
15. Rajpara SM, Botello AP, Townend J, Ormerod AD. Systematic review of dermoscopy and digital dermoscopy/artificial intelligence for the diagnosis of melanoma. Br J Dermatol 2009; 161:591-604
16. Rahman MM, Bhattacharya P. An integrated and interactive decision support system for automated melanoma recognition of dermoscopic images. Comput Med Imaging Graph 2010; 34:479-486
17. Pellacani G, Grana C, Seidenari S. Algorithmic reproduction of asymmetry and border cut-off parameters according to the ABCD rule for dermoscopy. J Eur Acad Dermatol Venereol 2006; 20:1214-1219 (Pubitemid 44614617)
18. Wighton P, Sadeghi M, Lee TK, Atkins MS. A fully automatic random Walker segmentation for skin lesions in a supervised setting. Med Image Comput Comput Assist Interv 2009; 12:1108-1115
19. Kockara S, Mete M, Chen B, Aydin K. Analysis of density based and fuzzy c-means clustering methods on lesion border extraction in dermoscopy images. BMC Bioinformatics 2010; 11 (Suppl 6):S26
20. Stanley RJ, Stoecker WV, Moss RH, et al. A basis function feature-based approach for skin lesion discrimination in dermatology dermoscopy images. Skin Res Technol 2008; 14:425-435
21. Mete M, Sirakov NM. Lesion detection in demoscopy images with novel density-based and active contour approaches. BMC Bioinformatics 2010; 11 (Suppl 6):S23
22. Plotnick RE, Gardner RH, Hargrove WW, et al. Lacunarity analysis: a general technique for the analysis of spatial patterns. Phys Rev E Stat Phys Plasmas Fluids Relat Interdiscip Topics 1996; 53:5461-5468 (Pubitemid 126598823)
23. Mandelbrot BB. The fractal geometry of nature. Basel: Birkhäuser; 1987
24. Gilmore S, Hofmann-Wellenhof R, Muir J, Soyer HP. Lacunarity analysis: a promising method for the automated assessment of melanocytic naevi and melanoma. PLoS One 2009; 4:e7449
25. Christensen JH, Soerensen MB, Linghui Z, et al. Prediagnostic digital imaging prediction model to discriminate between malignant melanoma and benign pigmented skin lesion. Skin Res Technol 2010; 16:98-108
26. Vander HY, Naeyaert JM. Consistent cutaneous imaging with commercial digital cameras. Arch Dermatol 2006; 142:42-46 (Pubitemid 43107360)
27. LeAnder R, Chindam P, Das M, Umbaugh SE. Differentiation of melanoma from benign mimics using the relative-color method. Skin Res Technol 2010; 16:297-304
28. Friedmann PS, Pickard C, Ardern-Jones M, Bircher AJ. Drug-induced exanthemata: a source of clinical and intellectual confusion. Eur J Dermatol 2010; 20:255-259
29. Brahimi N, Routier E, Raison-Peyron N, et al. A three-year-analysis of fixed drug eruptions in hospital settings in France. Eur J Dermatol 2010; 20:461-464
30. Ziemer M, Goetze S, Juhasz K, Elsner P. Flagellate dermatitis as a bleomycinspecific adverse effect of cytostatic therapy: a clinical- histopathologic correlation. Am J Clin Dermatol 2011; 12:68-76
31. Ehmann LM, Ruzicka T, Wollenberg A. Cutaneous side-effects of EGFR inhibitors and their management. Skin Ther Lett 2011; 16:1-3
32. Chiou CC, Yang LC, Hung SI, et al. Clinicopathological features and prognosis of drug rash with eosinophilia and systemic symptoms: a study of 30 cases in Taiwan. J Eur Acad Dermatol Venereol 2008; 22:1044-1049
33. Kano Y, Shiohara T. The variable clinical picture of drug-induced hypersensitivity syndrome/drug rash with eosinophilia and systemic symptoms in relation to the eliciting drug. Immunol Allergy Clin North Am 2009; 29:481-501
34. Valeyrie-Allanore L, Roujeau JC. Denominations and classification of severe cutaneous adverse reactions to drugs: splitters versus mergers. Eur J Dermatol 2007; 17:359-360 (Pubitemid 47425898)
35. Auquier-Dunant A, Mockenhaupt M, Naldi L, et al. Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. Arch Dermatol 2002; 138:1019-1024 (Pubitemid 34875605)
36. Halevy S, Ghislain PD, Mockenhaupt M, et al. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol 2008; 58:25-32 (Pubitemid 350298142)
37. Mockenhaupt M, Viboud C, Dunant A, et al. Stevens-Johnsonsyndromeandtoxic epidermal necrolysis: assessment ofmedication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol 2008; 128:35-44 (Pubitemid 350249390)
38. Przybilla B, Aberer W, Bircher AJ, et al. Allergological approach to drug hypersensitivity reactions. J Dtsch Dermatol Ges 2008; 6:240-243 (Pubitemid 351361069)
39. Romano A, Demoly P. Recent advances in the diagnosis of drug allergy. Curr Opin Allergy Clin Immunol 2007; 7:299-303 (Pubitemid 47052016)
40. Aberer W, Bircher A, Romano A, et al. Drug provocation testing in the diagnosis of drug hypersensitivity reactions: general considerations. Allergy 2003; 58:854-863 (Pubitemid 37046682)
41. Romano A, Torres MJ, Castells M, et al. Diagnosis and management of drug hypersensitivity reactions. J Allergy Clin Immunol 2011; 127:S67-S73
42. Chung WH, Hung SI, Hong HS, et al. Medical genetics: a marker for Stevens- Johnson syndrome. Nature 2004; 428:486
43. Hung SI, Chung WH, Liou LB, et al. HLA-B-5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A 2005; 102:4134-4139
44. Phillips EJ, Chung WH, Mockenhaupt M, et al. Drug hypersensitivity: pharmacogenetics and clinical syndromes. J Allergy Clin Immunol 2011; 127:S60-S66
45. Mallal S, Nolan D, Witt C, et al. Association between presence of HLAB-5701; HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reversetranscriptase inhibitor abacavir. Lancet 2002; 359:727-732
46. Hetherington S, Hughes AR, Mosteller M, et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 2002; 359:1121-1122 (Pubitemid 34270738)
47. Doherty MJ. Algorithms for assessing the probability of an adverse drug reaction. Respir Med CME 2009; 2:63-67
48. Benahmed S, Picot MC, Hillaire-Buys D, et al. Comparison of pharmacovigilance algorithms in drug hypersensitivity reactions. Eur J Clin Pharmacol 2005; 61:537-541 (Pubitemid 41218825)
49. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30:239-245 (Pubitemid 12149145)
50. Sassolas B, Haddad C, Mockenhaupt M, et al. ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson Syndrome and toxic epidermal necrolysis: comparison with case-control analysis. Clin Pharmacol Ther 2010; 88:60-68
51. Thong BY, Tan TC. Epidemiology and risk factors for drug allergy. Br J Clin Pharmacol 2011; 71:684-700
52. Madabhushi A, Agner S, Basavanhally A, et al. Computer-aided prognosis: predicting patient and disease outcome via quantitative fusion of multiscale, multimodal data. Comput Med Imaging Graph 2011. [Epub ahead of print]
53. Bousquet PJ, Demoly P, Romano A, et al. Pharmacovigilance of drug allergy and hypersensitivity using the ENDA-DAHD database and the GALEN platform. The Galenda project. Allergy 2009; 64:194-203
54. Hauben M, Horn S, Reich L. Potential use of data-mining algorithms for the detection of 'surprise' adverse drug reactions. Drug Saf 2007; 30:143-155 (Pubitemid 46193064)
55. Batal I, Hauskrecht M. Mining clinical data using minimal predictive rules. AMIA Annu Symp Proc 2010; 2010:31-35